|
IN2012DN00313A
(enExample)
*
|
2003-06-27 |
2015-05-08 |
Amgen Fremont Inc |
|
|
EP2064325B1
(en)
|
2006-09-01 |
2011-12-07 |
Therapeutic Human Polyclonals, Inc. |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
|
HRP20140049T1
(hr)
|
2007-01-05 |
2014-02-28 |
University Of Zürich |
Anti beta-amiloid antitijela i njihova upotreba
|
|
DK2370466T3
(en)
|
2008-12-19 |
2015-08-03 |
Univ Zuerich |
Humane anti-alpha-synuclein-autoantistoffer
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
US9128101B2
(en)
|
2010-03-01 |
2015-09-08 |
Caris Life Sciences Switzerland Holdings Gmbh |
Biomarkers for theranostics
|
|
CA2795776A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers for disease
|
|
TWI636993B
(zh)
|
2010-10-27 |
2018-10-01 |
安美基公司 |
Ｄｋｋ１抗體及使用方法
|
|
CA2827952A1
(en)
|
2011-02-23 |
2012-11-01 |
Health Research, Inc. |
Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
|
|
CA2828000A1
(en)
*
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
|
US9255595B2
(en)
*
|
2011-04-29 |
2016-02-09 |
Bae Systems Information And Electronic Systems Integration Inc. |
Optical dome bezel
|
|
CA2839563C
(en)
*
|
2011-06-23 |
2019-10-29 |
Biogen Idec International Neuroscience Gmbh |
Anti-alpha synuclein binding molecules
|
|
WO2013074840A1
(en)
*
|
2011-11-15 |
2013-05-23 |
Allergan, Inc. |
Treatment of dry age related macular degeneration
|
|
UA115789C2
(uk)
*
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US10155820B2
(en)
|
2014-11-12 |
2018-12-18 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
CN105821029A
(zh)
*
|
2015-01-04 |
2016-08-03 |
彭霞 |
异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
|
|
CN108347906A
(zh)
*
|
2015-10-29 |
2018-07-31 |
豪夫迈·罗氏有限公司 |
具有共同轻链的转基因兔
|
|
CN106928355B
(zh)
*
|
2015-12-30 |
2020-09-29 |
广西医科大学 |
一种CD105纳米抗体Nb184
|
|
CN106928359B
(zh)
*
|
2015-12-30 |
2020-10-13 |
广西医科大学 |
一种CD105纳米抗体Nb59
|
|
RU2732502C2
(ru)
|
2016-02-10 |
2020-09-18 |
Ратгерс, Де Стейт Юниверсити Оф Нью Джерси |
Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis
|
|
CA3026066A1
(en)
*
|
2016-06-14 |
2017-12-21 |
Cedars-Sinai Medical Center |
Sensitization of tumors to therapies through endoglin antagonism
|
|
DK3672631T5
(da)
|
2017-08-22 |
2024-08-26 |
Biogen Ma Inc |
Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
|
|
CN108912212B
(zh)
*
|
2018-06-28 |
2019-08-30 |
中山大学附属口腔医院 |
一种与cd105特异性结合的多肽及其应用
|
|
WO2020106461A2
(en)
*
|
2018-11-08 |
2020-05-28 |
Celldex Therapeutics, Inc. |
Anti-mertk antibodies and methods of use thereof
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
WO2021207433A2
(en)
*
|
2020-04-07 |
2021-10-14 |
The Regents Of The University Of California |
Epitopes of sars-cov-2 neutralizing antibodies
|
|
CN112426526B
(zh)
*
|
2021-01-25 |
2021-04-06 |
北京达熙生物科技有限公司 |
一种nk细胞的制备方法及其在治疗癌症中的应用
|
|
CN112876538B
(zh)
*
|
2021-02-04 |
2022-09-30 |
福建医科大学 |
靶向新生血管标记物cd105的多肽及其应用
|
|
EP4301785A4
(en)
|
2021-03-05 |
2025-04-23 |
Atreca, Inc. |
EPHA2 ANTIBODIES
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
IL314048A
(en)
*
|
2022-01-24 |
2024-09-01 |
Genovac Antibody Discovery Llc |
Anti-alk1 antibodies and methods of using the same
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
EP4627096A1
(en)
|
2022-12-02 |
2025-10-08 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
CN121443743A
(zh)
|
2023-05-23 |
2026-01-30 |
赛纳生物技术公司 |
串联融合剂和相关脂质颗粒
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025045032A1
(zh)
*
|
2023-08-29 |
2025-03-06 |
应世生物科技(南京)有限公司 |
一种靶向cd105的抗体或其抗原结合片段及其应用
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
KR20250174161A
(ko)
*
|
2024-06-04 |
2025-12-12 |
한국과학기술연구원 |
엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도
|
|
TWI882851B
(zh)
*
|
2024-06-27 |
2025-05-01 |
蔡政育 |
基於專利技術元素整合之專利分析系統及其方法
|
|
WO2026017807A1
(en)
|
2024-07-18 |
2026-01-22 |
Beech Biotech Sa |
Compositions and uses thereof
|